• NatureSynthetic


Our Abpromise guarantee covers the use of ab86257 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Purity70 - 90% by HPLC.

  • FormLiquid
  • Additional notes

    - First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
    - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
    - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
    - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
    - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

    Information available upon request.

General Info

  • Alternative names
    • Batten disease protein
    • Battenin
    • BTS
    • Ceroid lipofuscinosis neuronal 3
    • Ceroid lipofuscinosis neuronal 3 juvenile
    • Ceroid lipofuscinosis neuronal 3 juvenile (Batten Spielmeyer Vogt disease)
    • CLN 3
    • CLN3
    • CLN3_HUMAN
    • JNCL
    • MGC102840
    • Protein CLN3
    see all
  • FunctionInvolved in microtubule-dependent, anterograde transport of late endosomes and lysosomes.
  • Involvement in diseaseDefects in CLN3 are the cause of neuronal ceroid lipofuscinosis type 3 (CLN3) [MIM:204200]; also known as Batten disease. A form of neuronal ceroid lipofuscinosis. Neuronal ceroid lipofuscinoses are progressive neurodegenerative, lysosomal storage diseases characterized by intracellular accumulation of autofluorescent liposomal material, and clinically by seizures, dementia, visual loss, and/or cerebral atrophy. The hallmark of CLN3 is the ultrastructural pattern of lipopigment with a fingerprint profile, which can have 3 different appearances: pure within a lysosomal residual body; in conjunction with curvilinear or rectilinear profiles; and as a small component within large membrane-bound lysosomal vacuoles. The combination of fingerprint profiles within lysosomal vacuoles is a regular feature of blood lymphocytes from patients with CLN3.
  • Sequence similaritiesBelongs to the battenin family.
  • Post-translational
    Highly glycosylated.
    Farnesylation is important for trafficking to lysosomes.
  • Cellular localizationLysosome membrane. Late endosome.
  • Information by UniProt

References for Human CLN3 peptide (ab86257)

ab86257 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab86257.
Please use the links above to contact us or submit feedback about this product.